Thursday, March 28, 2024

Helius Therapeutics

First key ‘Cannabis for pets’ study conducted

A New Zealand company that’s set to be among the first in the world to register cannabis medicines for pets has successfully completed its...

Helius appoints Director of R&D

Marten Vos has been appointed Director of Research & Development at Helius Therapeutics. “Helius is squarely focused on building and driving its R&D capability, with...

Candace Kinser appointed chair of Helius Therapeutics

Candace Kinser has been appointed chair of the board at Helius Therapeutics. The accomplished chief executive and non-executive board director brings significant experience in high-growth...

Helius celebrates female leadership in cannabis sector

Helius Therapeutics is taking time to reflect on Suffrage Day. On 19 September 1893, New Zealand became the first nation in the world to grant...

Helius forms advanced medicinal cannabis collaboration

New Zealand’s largest licenced medicinal cannabis company, Helius Therapeutics, has signed an agreement with Auckland University of Technology (AUT). It will see Helius working with AUT academics and doctoral...

Helius gains NZ’s first licence to manufacture cannabis medicines

New Zealand’s largest licenced medicinal cannabis company, Helius Therapeutics, has been issued with the industry’s first GMP (Good Manufacturing Practice) Licence to Manufacture Medicines by MedSafe. It allows the...